Chemomab Therapeutics

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After losing some value lately, a hammer chart pattern has been formed for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB), indicating that the stock has found support.

Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that CCL24 Activates Endothelial Cells in Specific Ways that Result in SSc-Associated Fibrosis -- TEL AVIV, Israel , Nov. 16, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported on its poster presentation at the American College of Rheumatology (ACR) Convergence 2023 conference.

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition—  —CM-101's Phase 2 SPRING Trial in PSC is Advancing Towards Completion of Enrollment with Top-line Readout Expected in 2H 2024— TEL AVIV, Israel , Nov. 15, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted CM-101 Fast Track designation for the treatment in adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease that can result in liver transplant, cancer and early death.

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

— New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101— —Oral Presentation of Proteomic Analyses in PSC Patients Provides Further Evidence that CCL24 Is a Key Driver of the Inflammatory and Fibrotic Processes Underlying PSC and Other Disorders— TEL AVIV, Israel , Nov. 13, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported on its oral and poster presentations at AASLD's The Liver Meeting® 2023, being held November 10-14, 2023.

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

— Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024— —Reiterates Guidance that Cash Reserves Are Sufficient to Fund the Company Through the End of 2024, with Decreasing Quarterly Cash Burn Expected to Continue— TEL AVIV, Israel , Nov. 9, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate update.

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

-- Chemomab's ADSs Will Continue to Trade on the Nasdaq Capital Market-- TEL AVIV, Israel , Nov. 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab", or the "Company"), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today disclosed that the Company received notice ("Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") on November 6, 2023 that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of its American Depositary Shares (the "ADSs") on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

TEL AVIV, Israel , Oct. 30, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will release its third quarter 2023 financial results and a business update on November 9, 2023 at 8:00 am Eastern Time.

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel , Oct. 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will present at major U.S. scientific conferences in November, including an oral presentation on primary sclerosing cholangitis and a poster at the AASLD The Liver Meeting® 2023, as well as a poster presentation on the role of Chemomab's CCL24 target in manifestations of systemic sclerosis at the American College of Rheumatology Convergence 2023.

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

-- CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in Primary Sclerosing Cholangitis (PSC)--- --CM-101 Phase 2 SPRING Trial in PSC is Advancing Towards Completion of Enrollment with Topline Readout Currently Targeted in Second Half of 2024-- TEL AVIV, Israel , Sept. 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Virtual presentation to be available starting on September 11, 2023, at 7 AM Eastern Time TEL AVIV, Israel , Aug. 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced that Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab, will present virtually at the H.C.

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

─On Track to Achieve CM-101 PSC Phase 2 Readout Expected in 2H2024— ─Extended Estimated Cash Runway Through PSC Readout and 2024 Year-End─ ─ Reported Positive Secondary Analysis of Data from CM-101 Phase 2 Liver Fibrosis Trial─ ─Successfully Implemented Senior Management Changes and Cost Saving Measures─ ─Published New Peer-Reviewed Articles and Presented Scientific Posters at European Medical Meetings Highlighting Therapeutic Potential of CM-101 for Treating Fibro-inflammatory Diseases─ TEL AVIV, Israel , Aug. 14, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2023, and provided a corporate update.

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

--Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody,   Interrupts the Fibro-Inflammatory Processes that Lead to PSC-- TEL AVIV, Israel , June 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced the publication of a peer-reviewed research article describing how CCL24 is a key driver of the fibrotic and inflammatory disease processes that result in primary sclerosing cholangitis (PSC), a rare disease of the bile ducts that has no FDA-approved treatments and is often fatal.

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

--New Proteomics Data Further Confirms the Relationship between CM-101's CCL24 Target and Primary Sclerosing Cholangitis (PSC) Disease Pathways-- --Provides Further Evidence that CM-101 Interrupts Fibrotic and Inflammatory Disease Processes Driven by Elevated Levels of CCL24-- TEL AVIV, Israel and VIENNA , June 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clinical rationale for the company's primary sclerosing cholangitis (PSC) program at EASL 2023, the Annual Congress of the European Association for the Study of the Liver, which took place June 21-24, 2023 in Vienna, Austria.

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

─Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation,          `Reinforcing and Extending Initial Study Results─  ─Provides New Insights into CM-101 Activity in NASH Patients at Greater Risk of Progressive Disease, Providing Further Support for CM-101's Direct Anti-inflammatory and Anti-fibrotic Dual Mode of Action─ ─Demonstrates Improvements in Key Biomarkers Associated with Other Fibrotic Liver Diseases                          Including Primary Sclerosing Cholangitis─  TEL AVIV, Israel , June 21, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101, its first-in-class CCL24-neutralizing antibody, in patients with non-alcoholic steatohepatitis (NASH).

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

─Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role ─ ─Sigal Fattal, Vice President Finance, Reappointed as CFO ─ ─On Track for PSC Phase 2 Topline Data Readout in Latter Part of 2024─ ─Implementing Further Reorganization and Efficiency Measures Intended to Extend Cash Runway to End of 2024, After Expected PSC Phase 2 Topline Data Readout─ ─Nissim Darvish, MD, PhD, Appointed Chairman of the Board─ TEL AVIV, Israel , June 5, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

── New Patient Data Further Implicates CCL24 in Fibrotic Disease Pathology and Prognosis and Supports Rationale for the Role of Chemomab's CCL24-Neutralizing Antibody CM-101in Systemic Sclerosis and Other Fibro-inflammatory Diseases ── MILAN and TEL AVIV, Israel , June 2, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a poster presentation at the 2023 European Congress of Rheumatology, hosted by the European Alliance of Association for Rheumatology (EULAR) and held in Milan, Italy May 31–June 3, 2023.

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─ ─Received FDA Clearance for CM-101 Systemic Sclerosis IND—Phase 2 Trial Expected to Open Mid-year─ ─Advancing Phase 2 PSC Trial and Enrolling Patients in Higher Dose Cohort ─ ─Extending Estimated Cash Runway Through First Half of 2024─  ─Company to Host Conference Call for Investors Today, May 11 at 8:00 am ET ─ TEL AVIV, Israel , May 11, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update.

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

TEL AVIV, Israel , April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2 – May 4, 2023.

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

TEL AVIV, Israel, April 12, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time.

Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

TEL AVIV, Israel , March 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will provide a Corporate Update on Monday, April 17, 2023, at 8:00 am Eastern Time.

Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023

TEL AVIV, Israel , March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time.

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.

News for Chemomab Therapeutics Stock (CMMB)